CytexOrtho
  • Home
  • Technology
  • News
  • Contact
  • About
    • Mission and Team
    • FAQ
    • Disclosures
Select Page

Corporate and Scientific Integrity Policy

by CytexOrtho | May 20, 2024 | Disclosures

    COI Policy View...

SEC Filings

by CytexOrtho | May 1, 2023 | Disclosures

This is the 2024 Form C-AR as required by the SEC.   2024 Form C-AR View...

Recent Posts

  • Cytex Ortho Approval For Clinical Trials
  • FDA Approves CytexOrtho Hip Human Clinical Trials – New Implants Aim to Regrow Cartilage to Repair Joints
  • “Harnessing the Body’s Powerful Ability to Heal”
  • “CytexOrtho shares the ‘secret sauce’ for its absorbable hip implants”
  • Newsletter June 2024

Recent Comments

  1. Steve Scheftic on Breakthrough Device Designation from the FDA
  • Follow
  • Follow
  • Follow
  • Follow

Products are in development. This is potential future technology and not approved by the FDA and not commercially available. The innovations described above are all currently in development. Features and performances of future technologies may vary. Access to future technologies are contingent upon regulatory approval. Approval timelines are subject to the regulatory process of individual countries and regions and not guaranteed.

© 2022 Cytex Therapeutics, Inc now DBA CytexOrtho. All rights reserved